137 related articles for article (PubMed ID: 32373975)
1. LncRNA FOXD2-AS1 stimulates glioma progression through inhibiting P53.
Zhao QS; Ying JB; Jing JJ; Wang SS
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4382-4388. PubMed ID: 32373975
[TBL] [Abstract][Full Text] [Related]
2. LncRNA SAMD12-AS1 down-regulates P53 to promote malignant progression of glioma.
Yu BX; Zou L; Li S; Du YL
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8456-8467. PubMed ID: 31646576
[TBL] [Abstract][Full Text] [Related]
3. Upregulated lncRNA CACNA1G-AS1 aggravates the progression of colorectal cancer by downregulating p53.
Wei LJ; Bai DM; Wang ZY; Liu BC
Eur Rev Med Pharmacol Sci; 2020 Jan; 24(1):130-136. PubMed ID: 31957825
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA FOXD2-AS1 promotes glioma malignancy and tumorigenesis via targeting miR-185-5p/CCND2 axis.
Shen F; Chang H; Gao G; Zhang B; Li X; Jin B
J Cell Biochem; 2019 Jun; 120(6):9324-9336. PubMed ID: 30520141
[TBL] [Abstract][Full Text] [Related]
5. Silencing lncRNA FOXD2-AS1 inhibits proliferation, migration, invasion and drug resistance of drug-resistant glioma cells and promotes their apoptosis via microRNA-98-5p/CPEB4 axis.
Gu N; Wang X; Di Z; Xiong J; Ma Y; Yan Y; Qian Y; Zhang Q; Yu J
Aging (Albany NY); 2019 Nov; 11(22):10266-10283. PubMed ID: 31770107
[TBL] [Abstract][Full Text] [Related]
6. LncRNA FOXD2-AS1 knockdown inhibits the resistance of human osteosarcoma cells to cisplatin by inhibiting miR-143 expression.
Zhang QQ; Xu SL; Ding C; Ma CC; Yuan TS; Hua CC; Wang XH
Eur Rev Med Pharmacol Sci; 2021 Jan; 25(2):678-686. PubMed ID: 33577022
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA GClnc1 promotes progression of colorectal cancer by inhibiting p53 signaling pathway.
Dong YX; Pang ZG; Zhang JC; Hu JQ; Wang LY
Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5705-5713. PubMed ID: 31298323
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNA FOXD2-AS1 promotes glioma cell cycle progression and proliferation through the FOXD2-AS1/miR-31/CDK1 pathway.
Wang J; Li B; Wang C; Luo Y; Zhao M; Chen P
J Cell Biochem; 2019 Dec; 120(12):19784-19795. PubMed ID: 31347720
[TBL] [Abstract][Full Text] [Related]
9. LncRNA FOXD2-AS1 accelerates the progression of cervical cancer via downregulating CDX1.
Chen DZ; Wang TF; Dai WC; Xu X; Chen PF
Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10234-10240. PubMed ID: 31841177
[TBL] [Abstract][Full Text] [Related]
10. Long noncoding FOXD2-AS1 is activated by CREB1 and promotes cell proliferation and metastasis in glioma by sponging miR-185 through targeting AKT1.
Dong H; Cao W; Xue J
Biochem Biophys Res Commun; 2019 Jan; 508(4):1074-1081. PubMed ID: 30553445
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of FOXD2-AS1 enhances proliferation and impairs differentiation of glioma stem cells by activating the NOTCH pathway via TAF-1.
Wang Y; Cheng Y; Yang Q; Kuang L; Liu G
J Cell Mol Med; 2022 May; 26(9):2620-2632. PubMed ID: 35419917
[TBL] [Abstract][Full Text] [Related]
12. LncRNA FOXD2-AS1 facilitates the progression of hepatocellular carcinoma by regulating TWIST1.
Chen G; Zhang WL; Zhang SM; Tang KL; Zhang Y
Eur Rev Med Pharmacol Sci; 2023 May; 27(10):4536-4543. PubMed ID: 37259735
[TBL] [Abstract][Full Text] [Related]
13. LncRNA FOXD2-AS1 regulates chondrocyte proliferation in osteoarthritis by acting as a sponge of miR-206 to modulate CCND1 expression.
Cao L; Wang Y; Wang Q; Huang J
Biomed Pharmacother; 2018 Oct; 106():1220-1226. PubMed ID: 30119190
[TBL] [Abstract][Full Text] [Related]
14. LncRNA FOXC2-AS1 stimulates proliferation of melanoma via silencing p15 by recruiting EZH2.
Xu DF; Tao XH; Yu Y; Teng Y; Huang YM; Ma JW; Fan YB
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(17):8940-8946. PubMed ID: 32964984
[TBL] [Abstract][Full Text] [Related]
15. LncRNA FOXD2-AS1 plays an oncogenic role in hepatocellular carcinoma through epigenetically silencing CDKN1B(p27) via EZH2.
Xu K; Zhang Z; Qian J; Wang S; Yin S; Xie H; Zhou L; Zheng S
Exp Cell Res; 2019 Jul; 380(2):198-204. PubMed ID: 31004581
[TBL] [Abstract][Full Text] [Related]
16. Curcumol inhibits malignant biological behaviors and TMZ-resistance in glioma cells by inhibiting long noncoding RNA FOXD2-As1-promoted EZH2 activation.
Lv X; Sun J; Hu L; Qian Y; Fan C; Tian N
Aging (Albany NY); 2021 Nov; 13(21):24101-24116. PubMed ID: 34739394
[TBL] [Abstract][Full Text] [Related]
17. EGR1-induced upregulation of lncRNA FOXD2-AS1 promotes the progression of hepatocellular carcinoma via epigenetically silencing DKK1 and activating Wnt/β-catenin signaling pathway.
Lei T; Zhu X; Zhu K; Jia F; Li S
Cancer Biol Ther; 2019; 20(7):1007-1016. PubMed ID: 30929558
[TBL] [Abstract][Full Text] [Related]
18. [FOXD2-AS1 is corelated with clinicopathological parameter of laryngeal carcinoma and promote cancer cell proliferation].
Chen W; Sun SG; Jiang MX; Li SS; Yuan K
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 May; 33(5):436-440. PubMed ID: 31163553
[No Abstract] [Full Text] [Related]
19. lncRNA FOXD2-AS1 Promotes the Retinoblastoma Cell Viability and Migration by Sponging miR-31.
Liang Y; Wang H; Song R; Yin X
Biomed Res Int; 2022; 2022():7723425. PubMed ID: 35782084
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA FOXD2-AS1 functions as a tumor promoter in colorectal cancer by regulating EMT and Notch signaling pathway.
Yang X; Duan B; Zhou X
Eur Rev Med Pharmacol Sci; 2017 Aug; 21(16):3586-3591. PubMed ID: 28925486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
